(P017) Prolonged Progression-Free Survival for Surgically Managed P16-Negative Squamous Cell Carcinoma of the Oropharynx

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

It is well known that survival of patients with p16-negative oropharyngeal squamous cell carcinoma has a poor prognosis with standard chemoradiation. Studies have not compared the addition of surgery to chemoradiation as a method to improve survival. This study was designed to assess the benefit in progression-free survival (PFS) based on p16 status when surgery is included as part of the treatment paradigm for patients with squamous cell carcinoma of the oropharynx.

Eva M. Suarez, MD, Anand Sharma, MD, Kent Armeson, MS, Terry Day, MD; Medical University of South Carolina

Purpose: It is well known that survival of patients with p16-negative oropharyngeal squamous cell carcinoma has a poor prognosis with standard chemoradiation. Studies have not compared the addition of surgery to chemoradiation as a method to improve survival. This study was designed to assess the benefit in progression-free survival (PFS) based on p16 status when surgery is included as part of the treatment paradigm for patients with squamous cell carcinoma of the oropharynx.

Methods: A single-institution retrospective analysis identified 120 patients who were treated for stage III or IV oropharynx squamous cell carcinoma that was tested for p16 overexpression. Patients either received surgery followed by postoperative radiation or chemoradiation, as indicated by final pathology (S + RT/CRT), or definitive chemoradiation (CRT). PFS, defined as the time from the completion from treatment until the first evidence of local or distant recurrence, was summarized and plotted using Kaplan-Meier methods. The log-rank test was used to compare survival distributions across treatment groups, with P < .05 indicating statistical significance.

Results: The median follow-up was 19 months. A total of 32 patients tested negative and 88 tested positive for p16 overexpression. In the p16-negative group, 10 were treated with S + RT/CRT and 22 had definitive CRT. In the p16-positive group, 37 patients were treated with S + RT/CRT and 51 had definitive CRT. In the p16-negative group, 62.5% of patients had recurrence of disease (3 in S + RT/CRT arm and 17 in CRT arm) compared with 15.9% in the p16-positive group (5 in S + RT/CRT arm and 9 in CRT arm). PFS for the p16-negative patients was statistically better for the S + RT/CRT group (mean PFS, 24.7 mo) versus CRT (mean PFS, 21.1 mo) (P = .031). Two-year PFS for the S + RT/CRT arm and CRT arm was 68.6% and 22%, respectively. This difference was not seen in the p16-positive population (mean PFS 46.8 mo for S + RT/CRT vs 36.0 mo for CRT; P = .440). Two-year PFS for the S + RT/CRT arm and CRT arm was 94.6% and 79.7%, respectively. There was no statistical difference in overall survival (OS) among the S + RT/CRT arm and CRT arm within the p16-negative group or the p16-positive group.

Conclusion: Surgery followed by RT or CRT improved PFS for patients with p16-negative oropharynx squamous cell carcinoma compared with those who received definitive chemoradiation. A prospective clinical trial is warranted and is in development to further assess treatment options in this group of patients.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content